摘要
目的探讨贝伐单抗结合TP方案化疗在晚期非小细胞肺癌(NSCLC)患者治疗中的应用效果分析.方法选取2022年1月—2023年9月我院收治的60例晚期NSCLC患者为研究对象,按随机数字表法将其分为对照组与观察组,各30例.对照组使用TP方案化疗,观察组使用贝伐单抗结合TP方案化疗.比较两组临床疗效、临床症状评分、血清标志物指标及生活质量.结果观察组临床总有效率为86.67%,高于对照组的60.00%,差异有统计学意义(P<0.05);治疗后,观察组临床症状评分、血清癌胚抗原、神经元特异性烯醇化酶、血管内皮生长因子水平均低于对照组,生命质量核心问卷评分高于对照组,组间差异有统计学意义(P<0.05).结论贝伐单抗联合TP方案化疗治疗晚期NSCLC患者效果显著,可有效改善患者临床症状,降低血清标志物指标,提高其生存质量.
Objective To investigate the effect of chemotherapy with bevacizumab combined with TP regimen in the treatment of advanced non-small cell lung cancer(NSCLC).Methods 60 patients with advanced NSCLC admitted to our hospital from January 2022 to September 2023 were selected as the study objects,and were divided into a control group and an observation group according to random number table method,with 30 cases in each group.The control group received TP regimen chemotherapy,and the observation group received bevacizumab combined with TP regimen chemotherapy.The clinical efficacy,clinical symptom score,serum markers and quality of life of the two groups were compared.Results The clinical effect of observation group was 86.67%higher than 60.00%of the control group,the difference was statistically significant(P<0.05).After treatment,the clinical symptom score,serum carcinoembryonic antigen,neuronal specific enolase and vascular endothelial growth factor levels in observation group were lower than those in control group,and the score of Quality of Life core Questionnaire was higher than that in control group,with statistical significance between the two groups(P<0.05).Conclusion Chemotherapy with bevacizumab combined with TP regimen is effective in the treatment of advanced NSCLC patients,which can effectively improve clinical symptoms,reduce serum markers and improve their quality of life.
作者
姜新玲
JIANG Xinling(Department of Oncology,Qixia People's Hospital,Yantai Shandong,265300,China)
出处
《反射疗法与康复医学》
2024年第5期75-77,84,共4页
Reflexology And Rehabilitation Medicine
关键词
晚期非小细胞肺癌
TP化疗
贝伐单抗
疗效
血清标志物
Advanced non-small cell lung cancer
TP chemotherapy
Bevacizumab
Curative effect
Serum marker
作者简介
姜新玲(1969-),女,山东烟台人,本科,副主任医师,研究方向:肿瘤诊治。
